Affinity maturation of a novel antagonistic human monoclonal antibody with a long V_H CDR3 targeting the Class A GPCR formyl-peptide receptor 1

References

• Ye RD, Boulay F, Wang JM, Dahlgren C, Gerard C, Parmentier M, Serhan CN, Murphy PM. International union of basic and clinical pharmacology. LXXIII. Nomenclature for the formyl peptide receptor (FPR) family. Pharmacol Rev 2009; 61(2):119-61; PMID:19498085; http://dx.doi.org/10.1124/pr.109.001578
   PubMed Web of Science ®Google Scholar
• Boulay F, Tardif M, Brouchon L, Vignais P. Synthesis and use of a novel N-formyl peptide derivative to isolate a human N-formyl peptide receptor cDNA. Biochem Biophys Res Commun 1990; 168(3):1103-9; PMID:2161213; http://dx.doi.org/10.1016/0006-291X(90)91143-G
   PubMed Web of Science ®Google Scholar
• Migeotte I, Communi D, Parmentier M. Formyl peptide receptors: a promiscuous subfamily of G protein-coupled receptors controlling immune responses. Cytokine Growth Factor Rev 2006; 17(6):501-19; PMID:17084101; http://dx.doi.org/10.1016/j.cytogfr.2006.09.009
   PubMed Web of Science ®Google Scholar
• Li Y, Ye D. Molecular biology for formyl peptide receptors in human diseases. J Mol Med (Berl) 2013; 91(7): 781-9; PMID:23404331; http://dx.doi.org/10.1007/s00109-013-1005-5
   PubMed Web of Science ®Google Scholar
• Zhang Q, Raoof M, Chen Y, Sumi Y, Junger W, Brohi K, Itagaki K, Hauser CJ. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010; 464(7285): 104-7; PMID:20203610; http://dx.doi.org/10.1038/nature08780
   PubMed Web of Science ®Google Scholar
• Liu M, Zhao J, Chen K, Bian X, Wang C, Shi Y, Wang JM. G protein-coupled receptor FPR1 as a pharmacologic target in inflammation and human glioblastoma. Int Immunopharmacol 2012; 14(3):283-8; PMID:22863814; http://dx.doi.org/10.1016/j.intimp.2012.07.015
   PubMed Web of Science ®Google Scholar
• Webb DR, Handel TM, Kretz-Rommel A, Stevens RC. Opportunities for functional selectivity in GPCR antibodies. Biochem Pharmacol 2013; 85(2): 147-52; PMID:22975405; http://dx.doi.org/10.1016/j.bcp.2012.08.021
   PubMed Web of Science ®Google Scholar
• Niebauer RT, White JF, Fei Z, Grisshammer R. Characterization of monoclonal antibodies directed against the rat neurotensin receptor NTS1. J Recept Signal Transduct Res 2006; 26(5-6):395-415; PMID:17118789; http://dx.doi.org/10.1080/10799890600928228
   PubMed Web of Science ®Google Scholar
• Mancia F, Brenner-Morton S, Siegel R, Assur Z, Sun Y, Schieren I, Mendelsohn M, Axel R, Hendrickson WA. Production and characterization of monoclonal antibodies sensitive to conformation in the 5HT2c serotonin receptor. Proc Natl Acad Sci U S A. 2007; 104(11):4303-8; PMID:17360519; http://dx.doi.org/10.1073/pnas.0700301104
   PubMed Web of Science ®Google Scholar
• Hutchings CJ, Koglin M, Marshall FH. Therapeutic antibodies directed at G protein-coupled receptors. MAbs 2010; 2(6):594-606; PMID:20864805; http://dx.doi.org/10.4161/mabs.2.6.13420
   PubMed Web of Science ®Google Scholar
• Chen CR, McLachlan SM, Rapoport B. Suppression of thyrotropin receptor constitutive activity by a monoclonal antibody with inverse agonist activity. Endocrinology 2007; 148(5):2375-82; PMID:17272389; http://dx.doi.org/10.1210/en.2006-1754
   PubMed Web of Science ®Google Scholar
• Tohidkia MR, Asadi F, Barar J, Omidi Y. Selection of potential therapeutic human single-chain fv antibodies against cholecystokinin-B/gastrin receptor by phage display technology. BioDrugs 2013; 27(1):55-67; PMID:23344946; http://dx.doi.org/10.1007/s40259-012-0007-0
   PubMed Web of Science ®Google Scholar
• Ravn P, Madhurantakam C, Kunze S, Matthews E, Priest C, O’brien S, Collinson A, Papwort M, Fritsch-Fredin M, Benthem L, et al. Structural and pharmacological characterisation of novel potent and selective monoclonal antibody antagonists of glucose-dependent insulinotropic polypeptide receptor. J Biol Chem 2013; 288(27): 19760-72; PMID:23689510; http://dx.doi.org/10.1074/jbc.M112.426288
   PubMed Web of Science ®Google Scholar
• Allard B, Priam F, Deshayes F, Ducancel F, Boquet D, Wijkhuisen A, Couraud JY. Electroporation-aided DNA immunization generates polyclonal antibodies against the native conformation of human endothelin B receptor. DNA Cell Biol 2011; 30(9):727-37; PMID:21688998; http://dx.doi.org/10.1089/dna.2011.1239
   PubMed Web of Science ®Google Scholar
• McKnight A, Wilkinson D, Simmons G, Talbot S, Picard L, Ahuja M, Marsh M, Hoxie JA, Clapham PR. Inhibition of human immunodeficiency virus fusion by a monoclonal antibody to a coreceptor (CXCR4) is both cell type and virus strain dependent. J Virol 1997; 71(2):1692-6; PMID:8995702
   PubMed Web of Science ®Google Scholar
• Goetzl EJ, Dembrow D, Van Brocklyn JR, Graler M, Huang MC. An IgM-kappa rat monoclonal antibody specific for the type 1 sphingosine 1-phosphate G protein-coupled receptor with antagonist and agonist activities. Immunol Lett 2004; 93(1):63-9; PMID:15134901; http://dx.doi.org/10.1016/j.imlet.2004.02.007
   PubMed Web of Science ®Google Scholar
• Ji C, Brandt M, Dioszegi M, Jekle A, Schwoerer S, Challand S, Zhang J, Chen Y, Zautke L, Achhammer G et al. Novel CCR5 monoclonal antibodies with potent and broad-spectrum anti-HIV activities. Antiviral Res 2007; 74(2): 125-37; PMID:17166600; http://dx.doi.org/10.1016/j.antiviral.2006.11.003
   PubMed Web of Science ®Google Scholar
• Hagemann UB, Gunnarsson L, Geraudie S, Scheffer U, Griep RA, Reiersen H, Duncan AR, Kiprijanov SM. Fully human antagonistic antibodies against CCR4 potently inhibit cell signaling and chemotaxis. Plos One 2014;9(7) e103776; PMID:25080123; http://dx.doi.org/10.1371/journal.pone.0103776
   PubMed Web of Science ®Google Scholar
• Minter RR, Cohen ES, Wang B, Liang M, Vainshtein I, Rees G, Eghobamien L, Harrison P, Sims DA, Matthews C et al. Protein engineering and preclinical development of a GM-CSF receptor antibody for the treatment of rheumatoid arthritis. Br J Pharmacol 2013; 168(1):200-11; PMID:22913645; http://dx.doi.org/10.1111/j.1476-5381.2012.02173.x
   PubMed Web of Science ®Google Scholar
• Lowe D, Wilkinson T, Vaughan TJ. Affinity maturation approaches for antibody lead optimization. In: Wood CR, editor. Antibody Drug Discovery. London, UK: Imperial College Press; 2012. p. 85-120.
   Google Scholar
• Vargas HM, Amouzadeh HR, Engwall MJ. Nonclinical strategy considerations for safety pharmacology: evaluation of biopharmaceuticals. Expert Opinion on Drug Safety 2013; 12(1):91-102; PMID:23170873; http://dx.doi.org/10.1517/14740338.2013.745851
   PubMed Web of Science ®Google Scholar
• Kabat EA, Wu TT. Identical V region amino acid sequences and segments of sequences in antibodies of different specificities. Relative contributions of VH and VL gene, minigenes, and complementarity-determining regions to binding of antibody-combining sites. J Immunol 1991; 147:1709-19; PMID:1908882
   PubMed Web of Science ®Google Scholar
• Zemlin M, Klinger M, Link J, Zemlin C, Bauer K, Engler JA, Schroder HW Jr, Kirkham PM. Expressed murine and human CDR-H3 intervals of equal length exhibit distinct repertoires that differ in their amino acid composition and predicted range of structures. J Mol Biol 2003; 334(4):733-49; PMID:14636599; http://dx.doi.org/10.1016/j.jmb.2003.10.007
   PubMed Web of Science ®Google Scholar
• Collis AV, Brouwer AP, Martin AC. Analysis of the antigen combining site: correlations between length and sequence composition of the hypervariable loops and the nature of the antigen. J Mol Biol 2003; 325(2): 337-354; PMID:12488099; http://dx.doi.org/10.1016/S0022-2836(02)01222-6
   PubMed Web of Science ®Google Scholar
• Dhillon AK, Stanfield RL, Gorny MK, Williams C, Zolla-Pazner S, Wilson, IA. Structure determination of an anti-HIV-1 Fab 447-52D-peptide complex from an epitaxially twinned data set. Acta Crystallogr D Biol Crystallogr. 2008; 64(Pt 7):792-802; PMID:8566514; http://dx.doi.org/10.1107/S0907444908013978
   PubMed Web of Science ®Google Scholar
• Ring AM, Manglik A, Kruse AC, Enos MD, Weis WI, Garcia KC, Kobilka BK. Adrenaline-activated structure of beta-adrenoceptor stabilized by an engineered nanobody. Nature 2013; 502(7472):575-9; PMID:24056936; http://dx.doi.org/10.1038/nature12572
   PubMed Web of Science ®Google Scholar
• Tillotson BJ, de Larrinoa IF, Skinner CA, Klavas DM, Shusta EV. Antibody affinity maturation using yeast display with detergent-solubilized membrane proteins as antigen sources. Protein Eng Des Sel 2013; 26(2): 101-12; PMID:23109730; http://dx.doi.org/10.1093/protein/gzs077
   PubMed Web of Science ®Google Scholar
• Mirzabekov T, Kontos H, Farzan M, Marasco W, Sodroski J. Paramagnetic proteoliposomes containing a pure, native, and oriented seven-transmembrane segment protein, CCR5. Nat Biotechnol 2000; 18(6): 649-654; PMID:10835604; http://dx.doi.org/10.1038/76501
   PubMed Web of Science ®Google Scholar
• Hutchings CJ, Cseke G, Osborne G, Woolard J, Zhukov A, Koglin M, Jazayeri A, Pandya-Pathak J, Langmead CJ, Hill SJ et al. Monoclonal anti-beta 1-adrenergic receptor antibodies activate G protein signaling in the absence of beta-arrestin recruitment. MAbs 2014; 6(1):246-61; PMID:24253107; http://dx.doi.org/10.4161/mabs.27226
   PubMed Web of Science ®Google Scholar
• Sahagun-Ruiz A, Colla JS, Juhn J, Gao JL, Murphy PM, McDermott DH. Contrasting evolution of the human leukocyte N-formylpeptide receptor subtypes FPR and FPRL1R. Genes Immun 2001; 2(6):335-42; PMID:11607790; http://dx.doi.org/10.1038/sj.gene.6363787
   PubMed Web of Science ®Google Scholar
• Kilpatrick KE, Wring SA, Walker DH, Macklin MD, Payne JA, Su JL, Champion BR, Catterson B, McIntyre GD. Rapid development of affinity matured monoclonal antibodies using RIMMS. Hybridoma 1997; 16(4): 381-9; PMID:9309429; http://dx.doi.org/10.1089/hyb.1997.16.381
   PubMed Web of Science ®Google Scholar
• Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256(5517):495-7; PMID:1172191; http://dx.doi.org/10.1038/256495a0
   PubMed Web of Science ®Google Scholar
• Kunkel TA, Roberts JD, Zakour RA. Rapid and efficient site-specific mutagenesis without phenotypic selection. Methods Enzymol 1987; 154:367-82; PMID:3323813; http://dx.doi.org/10.1016/0076-6879(87)54085-X
   PubMed Web of Science ®Google Scholar
• Oganesyan V, Gao C, Shirinian L, Wu H, Dall'Acqua WF. Structural characterization of a human fc fragment engineered for lack of effector functions. Acta Crystallogr D Biol Crystallogr. 2008; 64(Pt 6): 700-4; PMID:18560159
   PubMed Web of Science ®Google Scholar
• Vonrhein C, Flensburg C, Keller P, Sharff A, Smart O, Paciorek W, Womack T, Bricogne G. Data processing and analysis with the autoPROC toolbox. Acta Crystallogr D Biol Crystallogr 2011; 67(Pt 4): 293-302; PMID:21460447; http://dx.doi.org/10.1107/S0907444911007773
   PubMed Web of Science ®Google Scholar
• Faber C, Shan L, Fan Z, Guddat LW, Furebring C, Ohlin M, Borrbaeck CA, Edmundson AB. Three-dimensional structure of a human fab with high affinity for tetanus toxoid. Immunotechnology 1998; 3(4): 253-70; PMID:9530559; http://dx.doi.org/10.1016/S1380-2933(97)10003-3
   PubMedGoogle Scholar
• Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of coot. Acta Crystallogr D Biol Crystallogr 2010; 66(Pt 4):486-501; PMID:20383002; http://dx.doi.org/10.1107/S0907444910007493
   PubMed Web of Science ®Google Scholar
• Bricogne G, Blanc E, Brandl M, Flensburg C, Keller P, Paciorek W, Roversi P, Sharff A, Smart OS, Vonrhein C et al. 2011. BUSTER version 2.11.5. Cambridge, UK: Global Phasing Ltd.
   Google Scholar
• Smart OS, Womack TO, Flensburg C, Keller P, Paciorek W, Sharff A, Vonrhein C, Bricogne G. Exploiting structure similarity in refinement: automated NCS and target-structure restraints in BUSTER. Acta Crystallogr D Biol Crystallogr 2012; 68(Pt 4): 368-80; PMID:22505257; http://dx.doi.org/10.1107/S0907444911056058
   PubMed Web of Science ®Google Scholar
• Robert R, Streltsov VA, Newman J, Pearce LA, Wark KL, Dolezal O. Germline humanization of a murine abeta antibody and crystal structure of the humanized recombinant fab fragment. Protein Sci 2010; 19(2): 299-308; PMID:20014445; http://dx.doi.org/10.1002/pro.312
   PubMed Web of Science ®Google Scholar
• Burke V, Williams C, Sukumaran M, Kim SS, Li H, Wang XH, Gorny MK, Zollar-Pazner S, Kong XP. Structural basis of the cross-reactivity of genetically related human anti-HIV-1 mAbs: implications for design of V3-based immunogens. Structure 2009; 17(11): 1538-46; PMID:19913488; http://dx.doi.org/10.1016/j.str.2009.09.012
   PubMed Web of Science ®Google Scholar
• Wu B, Chien EY, Mol CD, Fenalti G, Liu W, Katritch V, Abagyan R, Brooun A, Wells P, Bi FC et al. Structures of the CXCR4 chemokine GPCR with small-molecule and cyclic peptide antagonists. Science 2010; 330(6007): 1066-71; PMID:20929726; http://dx.doi.org/10.1126/science.1194396
   PubMed Web of Science ®Google Scholar
• Wu H, Wacker D, Mileni M, Katritch V, Won Han G, Vardy E, Liu W, Thompson AA, Huang X, Carroll RI et al. Structure of the human κ-opioid receptor in complex with JDTic. Nature 2012; 485(7398): 327-32; PMID:22437504; http://dx.doi.org/10.1038/nature10939
   PubMed Web of Science ®Google Scholar